Real-world evidence for immunotherapy in the first-line or subsequent-line setting in extensive-stage small-cell lung cancer.

Ther Adv Med Oncol · 2025 · PMC12592661 · PMID 41209619

Europe PMC DOI

hedged sentence

0.2640

closest p · 5.3× alpha

0.2640

boldest claim

The sentences

did not reach statistical significancep = 0.264not close (p > 0.1)

Results demonstrated that patients who received WBRT ( n = 83, 38.7%) exhibited a longer median OS of 17.97 months (95% CI, 15.453–20.487) versus 14.27 months (95% CI, 12.590–15.943) for those who did not receive WBRT, but it did not reach statistical significance ( p = 0.264, Figure 4(b) ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.